We use cookies to ensure that we give you the best experience on our website Learn more

Jun 29, 2018

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

21 / IMPROVEMENT OF QUALITY OF LIFE FOR ADVANCED CANCER PATIENT WITH INJECTION OF COMPLEMENTARY PG2 - A DOUBLE BLIND, MULTI-CENTER, RANDOMIZED PHASE IV STUDY

;

Lai;

Y.L.;

Wang;

C.H.;

Lin;

C.Y.;

Chen;

J.S.;

Ho;

C.L.;

Rau;

K.M.;

Tsai;

J.T.;

Chang;

C.S.;

Yeh;

S.P.

pg2 injection

palliative care

quality of life

phase iv study

Abstract

Abstract

thumbnail

Keywords

pg2 injection

palliative care

quality of life

phase iv study

Abstract

Introduction Quality of Life (QoL) was proposed as a survival predictor in advanced cancer patients. PG2 injection was extracted and purified from Astragalus membranaceus. In Traditional Chinese medicine, Astragalus membranaceus is commonly used to treat the deficiency of qi (vital energy). We evaluated the efficacy of PG2 injection in improving QoL in advanced cancer patient with or without palliative radiotherapeutic or chemotherapeutic treatments in this study. Objectives The aim of this study was to evaluate the effect of PG2 injection on QoL in advanced progressed cancer patients under standard palliative care. Methods Patients with advanced cancer receiving standard palliative care were enrolled and randomized at a 1:1 ratio into two arms of PG2 injection treatment: 500mg dose (500mg in 500ml saline, 3 times per week for 4 weeks) or 250mg dose (250mg in 500ml saline, 3 times per week for 4 weeks) for two cycles. Symptoms and Quality of Life Assessments were analyzed by 11 questions (SS11) from European Organization for Research and Treatment of Cancer QoL Questionnaire (EORTC QLQ-C30). Patients were divided into untreated, palliative chemotherapy treated, and palliative radiotherapy treated groups for analysis. Results Three hundred and ten patients were enrolled in this study. High and low doses of PG2 injection significantly improved patients’ appetite loss (p<0.0001, p=0.0004), fatigue (p<0.0001, p<0.0001), insomnia (p=0.0002, p<0.00001), and global QoL (p<0.0001, p<0.0001) after two cycles of treatments. Patients with or without therapeutic treatments were both analyzed. Conclusions PG2 injection can significantly improve several indicators for QoL in advanced cancer patients without safety concern.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.